BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hayes CN, Imamura M, Aikata H, Chayama K. Genetics of IL28B and HCV--response to infection and treatment. Nat Rev Gastroenterol Hepatol. 2012;9:406-417. [PMID: 22641049 DOI: 10.1038/nrgastro.2012.101] [Cited by in Crossref: 77] [Cited by in F6Publishing: 74] [Article Influence: 7.7] [Reference Citation Analysis]
Number Citing Articles
1 Madsen LW, Christensen PB, Øvrehus A, Bryde DMS, Holm DK, Lillevang ST, Nielsen C. Immunological Characteristics of Patients Receiving Ultra-Short Treatment for Chronic Hepatitis C. Front Cell Infect Microbiol 2022;12:885824. [DOI: 10.3389/fcimb.2022.885824] [Reference Citation Analysis]
2 Shen C, Ge Z, Dong C, Wang C, Shao J, Cai W, Huang P, Fan H, Li J, Zhang Y, Yue M. Genetic Variants in KIR/HLA-C Genes Are Associated With the Susceptibility to HCV Infection in a High-Risk Chinese Population. Front Immunol 2021;12:632353. [PMID: 34220799 DOI: 10.3389/fimmu.2021.632353] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
3 Cheng X, Uchida T, Xia Y, Umarova R, Liu CJ, Chen PJ, Gaggar A, Suri V, Mücke MM, Vermehren J, Zeuzem S, Teraoka Y, Osawa M, Aikata H, Tsuji K, Mori N, Hige S, Karino Y, Imamura M, Chayama K, Liang TJ. Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection. J Clin Invest 2020;130:3205-20. [PMID: 32163375 DOI: 10.1172/JCI135616] [Cited by in Crossref: 19] [Cited by in F6Publishing: 27] [Article Influence: 19.0] [Reference Citation Analysis]
4 Arayasongsak U, Naka I, Ohashi J, Patarapotikul J, Nuchnoi P, Kalambaheti T, Sa-Ngasang A, Chanama S, Chaorattanakawee S. Genetic association study of interferon lambda 3, CD27, and human leukocyte antigen-DPB1 with dengue severity in Thailand. BMC Infect Dis 2020;20:948. [PMID: 33308178 DOI: 10.1186/s12879-020-05636-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Huschka H, Mihm S. Interferon-lambda (IFNL) germline variations and their significance for HCC and PDAC progression: an analysis of The Cancer Genome Atlas (TCGA) data. BMC Cancer 2020;20:1131. [PMID: 33228589 DOI: 10.1186/s12885-020-07589-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
6 de Brito WB, Queiroz MAF, da Silva Graça Amoras E, Lima SS, da Silva Conde SRS, dos Santos EJM, Cayres-vallinoto IMV, Ishak R, Vallinoto ACR. The TGFB1 -509C/T polymorphism and elevated TGF-β1 levels are associated with chronic hepatitis C and cirrhosis. Immunobiology 2020;225:152002. [DOI: 10.1016/j.imbio.2020.152002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Hashempour T, Dehghani B, Musavi Z, Moayedi J, Hasanshahi Z, Sarvari J, Hosseini SY, Hosseini E, Moeini M, Merat S. Impact of IL28 Genotypes and Modeling the Interactions of HCV Core Protein on Treatment of Hepatitis C. Interdiscip Sci 2020;12:424-37. [PMID: 32656614 DOI: 10.1007/s12539-020-00382-8] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Zhao J, Zhang X, Fang L, Pan H, Shi J. Association between IL28B Polymorphisms and Outcomes of Hepatitis B Virus Infection: A meta-analysis. BMC Med Genet 2020;21:88. [PMID: 32357928 DOI: 10.1186/s12881-020-01026-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
9 Hou W, Qiao K, Huo Z, Du Y, Wang C, Syn WK. Association of IFNL3 rs12979860 polymorphism with HCV-related hepatocellular carcinoma susceptibility in a Chinese population. Clin Exp Gastroenterol 2019;12:433-9. [PMID: 31807049 DOI: 10.2147/CEG.S206194] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Jhaveri R. "Here Today, Gone Tomorrow" or "Here Today, Stay a Long While": The Divergent Paths of Two Host Factors Important in Viral Infections. Clin Ther 2019;41:1907-11. [PMID: 31447128 DOI: 10.1016/j.clinthera.2019.07.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Sezgin E, An P, Winkler CA. Host Genetics of Cytomegalovirus Pathogenesis. Front Genet 2019;10:616. [PMID: 31396258 DOI: 10.3389/fgene.2019.00616] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
12 Raja R, Baral S, Dixit NM. Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon-free treatment era. Immunol Rev 2018;285:55-71. [PMID: 30129199 DOI: 10.1111/imr.12689] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
13 Rivett L, Alexander G. Is the conquest of Hepatitis C imminent? Expert Rev Mol Med 2019;21:e3. [PMID: 30909984 DOI: 10.1017/erm.2019.3] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Helal TEA, Radwan NA, Mahmoud HA, Zaki AM, Ahmed NS, Wahib AA, Aref AM. The role of hepatic progenitor cells in predicting response to therapy in Egyptian patients with chronic hepatitis C, genotype 4. Afr Health Sci 2019;19:1411-21. [PMID: 31148968 DOI: 10.4314/ahs.v19i1.14] [Reference Citation Analysis]
15 Ali Q, Kalam I, Ullah S, Jamal A, Imran M, Ullah S, Iqbal K, Waqar AB. Predictive value of IL-28B rs12979860 variants for peg-IFN, sofosbuvir plus ribavirin treatment of HCV infection in Pakistani population. Per Med 2018;15:503-10. [PMID: 30383478 DOI: 10.2217/pme-2018-0012] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Ramamurthy N, Marchi E, Ansari MA, Pedergnana V, Mclean A, Hudson E, Bowden R, Spencer CCA, Barnes E, Klenerman P; STOP HCV consortium. Impact of Interferon Lambda 4 Genotype on Interferon-Stimulated Gene Expression During Direct-Acting Antiviral Therapy for Hepatitis C. Hepatology 2018;68:859-71. [PMID: 29534310 DOI: 10.1002/hep.29877] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
17 Venugopal V, Padmanabhan P, Raja R, Dixit NM. Modelling how responsiveness to interferon improves interferon-free treatment of hepatitis C virus infection. PLoS Comput Biol 2018;14:e1006335. [PMID: 30001324 DOI: 10.1371/journal.pcbi.1006335] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
18 Chiu KW, Nakano T, Chen KD, Hu TH, Lin CC, Hsu LW, Chen CL, Goto S. Identification of IL-28B Genotype Modification in Hepatocytes after Living Donor Liver Transplantation by Laser Capture Microdissection and Pyrosequencing Analysis. Biomed Res Int 2018;2018:1826140. [PMID: 29686997 DOI: 10.1155/2018/1826140] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Tashi T, Swierczek S, Kim SJ, Salama ME, Song J, Heikal N, King KY, Hickman K, Litton S, Prchal JT. Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses. Leukemia 2018;32:1830-3. [PMID: 29556018 DOI: 10.1038/s41375-018-0080-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
20 Hashem M, Jhaveri R, Saleh DA, Sharaf SA, El-Mougy F, Abdelsalam L, Shardell MD, El-Ghazaly H, El-Kamary SS. Spontaneous Viral Load Decline and Subsequent Clearance of Chronic Hepatitis C Virus in Postpartum Women Correlates With Favorable Interleukin-28B Gene Allele. Clin Infect Dis 2017;65:999-1005. [PMID: 28903504 DOI: 10.1093/cid/cix445] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
21 Naeemi H, Aslam R, Raza SM, Shahzad MA, Naz S, Manzoor S, Khaliq S. Distribution of IL28B and IL10 polymorphisms as genetic predictors of treatment response in Pakistani HCV genotype 3 patients. Arch Virol 2018;163:997-1008. [PMID: 29340806 DOI: 10.1007/s00705-018-3711-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
22 Wilson JL, Altman RB. Biomarkers: Delivering on the expectation of molecularly driven, quantitative health. Exp Biol Med (Maywood). 2018;243:313-322. [PMID: 29199461 DOI: 10.1177/1535370217744775] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
23 Liang PC, Lin PC, Huang CI, Huang CF, Yeh ML, Zeng YS, Hsu WY, Hsieh MY, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Chiou SS, Yu ML. The treatment outcome and impact on blood transfusion demand of Peg-interferon/ribavirin in thalassemic patients with chronic hepatitis C. J Formos Med Assoc 2018;117:14-23. [PMID: 29097076 DOI: 10.1016/j.jfma.2017.10.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
24 Koutb F, Abdel-Rahman S, Hassona E, Haggag A. Association of C-myc and p53 Gene Expression and Polymorphisms with Hepatitis C (HCV) Chronic Infection, Cirrhosis and Hepatocellular Carcinoma (HCC) Stages in Egypt. Asian Pac J Cancer Prev 2017;18:2049-57. [PMID: 28843220 DOI: 10.22034/APJCP.2017.18.8.2049] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
25 Cheng CH, Lin CC, Chen HL, Lin IT, Wu CH, Lee YK, Wong MW, Bair MJ. High frequencies of a favorable IL-28B rs8099917 polymorphism and the clinical implications in patients with HCV in one multiracial area of Taiwan. Kaohsiung J Med Sci 2017;33:510-5. [PMID: 28962822 DOI: 10.1016/j.kjms.2017.06.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
26 Lu M, Lewis CM, Traylor M. Pharmacogenetic testing through the direct-to-consumer genetic testing company 23andMe. BMC Med Genomics 2017;10:47. [PMID: 28629370 DOI: 10.1186/s12920-017-0283-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
27 Novotny D, Roubalova L, Aiglova K, Bednarikova J, Bartkova M. IL28B genotyping and treatment of HCV infected subjects. Asian Biomedicine 2014;8:445-52. [DOI: 10.5372/1905-7415.0804.313] [Reference Citation Analysis]
28 Palenzuela Gardón D, Guillen IA, Fernández JR, Camacho H, Estevez ZC, Dueñas S, Alvares-Lajonchere L, Amador Y, Martinez-Donato G, Han J, Zhang Z, Zhang X, Gao Y, Campaña JR, Novoa LI. Assessment of IL-28: rs12979860 and rs8099917 Polymorphisms in a Cohort of Cuban Chronic HCV Genotype 1b Patients. J Biomol Tech 2017;28:80-6. [PMID: 28058039 DOI: 10.7171/jbt.17-2801-001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
29 Sultana C, Oprişan G, Teleman MD, Dinu S, HepGen 88/2012 Project Team, Oprea C, Voiculescu M, Ruta S. Impact of hepatitis C virus core mutations on the response to interferon-based treatment in chronic hepatitis C. World J Gastroenterol 2016; 22(37): 8406-8413 [PMID: 27729747 DOI: 10.3748/wjg.v22.i37.8406] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
30 Meanwell NA. 2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph. J Med Chem 2016;59:7311-51. [PMID: 27501244 DOI: 10.1021/acs.jmedchem.6b00915] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
31 Daneshvar M, Nikbin M, Talebi S, Javadi F, Aghasadeghi MR, Mahmazi S, Sadat SM. Role of IL28-B Polymorphism (rs12979860) on Sustained Virological Response to Pegylated Interferon/Ribavirin in Iranian Patients With Chronic Hepatitis C. Iran Red Crescent Med J 2016;18:e28566. [PMID: 28144454 DOI: 10.5812/ircmj.28566] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
32 Shuldiner SR, Gong L, Muir AJ, Altman RB, Klein TE. PharmGKB summary: peginterferon-α pathway. Pharmacogenet Genomics 2015;25:465-74. [PMID: 26111151 DOI: 10.1097/FPC.0000000000000158] [Reference Citation Analysis]
33 Rizk HH, Hamdy NM, Al-Ansari NL, El-Mesallamy HO. Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4. PLoS One 2016;11:e0153895. [PMID: 27100663 DOI: 10.1371/journal.pone.0153895] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
34 Jiang DK, Wu X, Qian J, Ma XP, Yang J, Li Z, Wang R, Sun L, Liu F, Zhang P, Zhu X, Wu J, Chen K, Conran C, Zheng SL, Lu D, Yu L, Liu Y, Xu J. Genetic variation in STAT4 predicts response to interferon-α therapy for hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2016;63:1102-11. [PMID: 26704347 DOI: 10.1002/hep.28423] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
35 Rivero-Juárez A, Rivero A. Sustained virological response with sofosbuvir and ledipasvir for hepatitis C virus genotype 5. Lancet Infect Dis 2016;16:392-3. [PMID: 26803445 DOI: 10.1016/S1473-3099(16)00018-9] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
36 Dzekova-Vidimliski P, Nikolov IG, Matevska-Geshkovska N, Boyanova Y, Nikolova N, Romanciuc G, Dumitrascu D, Caloska-Ivanova V, Joksimovic N, Antonov K, Mateva L, Rostaing L, Dimovski A, Sikole A. Genetic predictors of the response to the treatment of hepatitis C virus infection. Bosn J Basic Med Sci 2015;15:55-9. [PMID: 26614853 DOI: 10.17305/bjbms.2015.632] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
37 Chandramohan V, Kaphle A, Chekuri M, Gangarudraiah S, Bychapur Siddaiah G. Evaluating Andrographolide as a Potent Inhibitor of NS3-4A Protease and Its Drug-Resistant Mutants Using In Silico Approaches. Adv Virol 2015;2015:972067. [PMID: 26587022 DOI: 10.1155/2015/972067] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
38 Lazear HM, Nice TJ, Diamond MS. Interferon-λ: Immune Functions at Barrier Surfaces and Beyond. Immunity 2015;43:15-28. [PMID: 26200010 DOI: 10.1016/j.immuni.2015.07.001] [Cited by in Crossref: 253] [Cited by in F6Publishing: 235] [Article Influence: 36.1] [Reference Citation Analysis]
39 Angulo J, Pino K, Echeverría-Chagas N, Marco C, Martínez-Valdebenito C, Galeno H, Villagra E, Vera L, Lagos N, Becerra N, Mora J, Bermúdez A, Cárcamo M, Díaz J, Miquel JF, Ferrés M, López-Lastra M. Association of Single-Nucleotide Polymorphisms in IL28B, but Not TNF-α, With Severity of Disease Caused by Andes Virus. Clin Infect Dis 2015;61:e62-9. [PMID: 26394672 DOI: 10.1093/cid/civ830] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
40 Kakati B, Seetharam A. Hepatitis C Recurrence after Orthotopic Liver Transplantation: Mechanisms and Management. J Clin Transl Hepatol 2014;2:189-96. [PMID: 26355427 DOI: 10.14218/JCTH.2014.00016] [Reference Citation Analysis]
41 Dzekova-Vidimliski P, Nikolov IG, Matevska-Geshkovska N, Mena S, Rostaing L, Dimovski A, Sikole A. Single nucleotide polymorphisms near IL28B gene and response to treatment of chronic hepatitis C in hemodialysis patients. Ren Fail 2015;37:1180-4. [PMID: 26156685 DOI: 10.3109/0886022X.2015.1061872] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
42 Friborg J, Ross-Macdonald P, Cao J, Willard R, Lin B, Eggers B, McPhee F. Impairment of type I but not type III IFN signaling by hepatitis C virus infection influences antiviral responses in primary human hepatocytes. PLoS One. 2015;10:e0121734. [PMID: 25826356 DOI: 10.1371/journal.pone.0121734] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
43 Azam S, Manzoor S, Imran M, Ashraf J, Ashraf S, Resham S, Ghani E. Role of interferon gamma and tumor necrosis factor-related apoptosis-inducing ligand receptor 1 single nucleotide polymorphism in natural clearance and treatment response of HCV infection. Viral Immunol 2015;28:222-8. [PMID: 25798684 DOI: 10.1089/vim.2014.0111] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
44 Jiménez-Sousa MA, Rallón N, Berenguer J, Pineda-Tenor D, López JC, Soriano V, Guzmán-Fulgencio M, Cosín J, Retana D, García-Álvarez M, Miralles P, Benito JM, Resino S. TLR3 polymorphisms are associated with virologic response to hepatitis C virus (HCV) treatment in HIV/HCV coinfected patients. J Clin Virol 2015;65:62-7. [PMID: 25766991 DOI: 10.1016/j.jcv.2015.02.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
45 Griffiths SJ, Dunnigan CM, Russell CD, Haas JG. The Role of Interferon-λ Locus Polymorphisms in Hepatitis C and Other Infectious Diseases. J Innate Immun 2015;7:231-42. [PMID: 25634147 DOI: 10.1159/000369902] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
46 Riva E, Scagnolari C, Turriziani O, Antonelli G. Hepatitis C virus and interferon type III (interferon-λ3/interleukin-28B and interferon-λ4): genetic basis of susceptibility to infection and response to antiviral treatment. Clin Microbiol Infect 2014;20:1237-45. [PMID: 25273834 DOI: 10.1111/1469-0691.12797] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
47 Baclig MO, Reyes KG, Mapua CA, Gopez-Cervantes J, Natividad FF; St. Luke’s Liver Diseases Study Group. Frequency of interleukin 28B rs12979860 C>T variants in Filipino patients chronically infected with hepatitis B virus. Mol Biol Rep 2015;42:673-9. [PMID: 25391769 DOI: 10.1007/s11033-014-3814-1] [Reference Citation Analysis]
48 Kaczor MP, Seczyńska M, Szczeklik W, Sanak M. IL28B polymorphism (rs12979860) associated with clearance of HCV infection in Poland: systematic review of its prevalence in chronic hepatitis C patients and general population frequency. Pharmacol Rep 2015;67:260-6. [PMID: 25712648 DOI: 10.1016/j.pharep.2014.10.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
49 Trinks J, Hulaniuk ML, Redal MA, Flichman D. Clinical utility of pharmacogenomics in the management of hepatitis C. Pharmgenomics Pers Med 2014;7:339-47. [PMID: 25382982 DOI: 10.2147/PGPM.S52624] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
50 Manuel O, Wójtowicz A, Bibert S, Mueller NJ, van Delden C, Hirsch HH, Steiger J, Stern M, Egli A, Garzoni C, Binet I, Weisser M, Berger C, Cusini A, Meylan P, Pascual M, Bochud PY; Swiss Transplant Cohort Study. Influence of IFNL3/4 polymorphisms on the incidence of cytomegalovirus infection after solid-organ transplantation. J Infect Dis 2015;211:906-14. [PMID: 25301956 DOI: 10.1093/infdis/jiu557] [Cited by in Crossref: 42] [Cited by in F6Publishing: 49] [Article Influence: 5.3] [Reference Citation Analysis]
51 Mihm S, Spengler U, Amanzada A, Ramadori G. Does the interferon-lambda rather than the interferon-alpha pathway determine the outcome of hepatitis C virus infection? Hepatology 2014;60:1437-9. [PMID: 25078395 DOI: 10.1002/hep.27345] [Reference Citation Analysis]
52 Abel L, Alcaïs A, Schurr E. The dissection of complex susceptibility to infectious disease: bacterial, viral and parasitic infections. Curr Opin Immunol 2014;30:72-8. [PMID: 25083600 DOI: 10.1016/j.coi.2014.07.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
53 Meager A, Heath A, Dilger P, Zoon K, Wadhwa M; Participants of the Collaborative Study. Standardization of human IL-29 (IFN-λ1): establishment of a World Health Organization international reference reagent for IL-29 (IFN-λ1). J Interferon Cytokine Res 2014;34:876-84. [PMID: 24955567 DOI: 10.1089/jir.2014.0015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
54 Ireton RC, Gale M Jr. Pushing to a cure by harnessing innate immunity against hepatitis C virus. Antiviral Res 2014;108:156-64. [PMID: 24907428 DOI: 10.1016/j.antiviral.2014.05.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
55 Padmanabhan P, Garaigorta U, Dixit NM. Emergent properties of the interferon-signalling network may underlie the success of hepatitis C treatment. Nat Commun 2014;5:3872. [PMID: 24834957 DOI: 10.1038/ncomms4872] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
56 Liu CH, Kao JH. Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa. Int J Nanomedicine 2014;9:2051-67. [PMID: 24812506 DOI: 10.2147/IJN.S41822] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 0.1] [Reference Citation Analysis]
57 Wilson JA, Sagan SM. Hepatitis C virus and human miR-122: insights from the bench to the clinic. Curr Opin Virol. 2014;7:11-18. [PMID: 24721497 DOI: 10.1016/j.coviro.2014.03.005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
58 Khudayberganova D, Sugiyama M, Masaki N, Nishida N, Mukaide M, Sekler D, Latipov R, Nataliya K, Dildora S, Sharapov S, Usmanova G, Raxmanov M, Musabaev E, Mizokami M. IL28B polymorphisms and clinical implications for hepatitis C virus infection in Uzbekistan. PLoS One 2014;9:e93011. [PMID: 24662995 DOI: 10.1371/journal.pone.0093011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
59 Chinnaswamy S. Genetic variants at the IFNL3 locus and their association with hepatitis C virus infections reveal novel insights into host-virus interactions. J Interferon Cytokine Res 2014;34:479-97. [PMID: 24555572 DOI: 10.1089/jir.2013.0113] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
60 Shin JI, Eisenhut M. miR-122, IL28B genotype and the response to interferon in chronic hepatitis C virus infection. Nat Rev Immunol 2013;13:902. [PMID: 24270782 DOI: 10.1038/nri3463-c1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
61 Larrubia JR, Lokhande MU, Moreno-Cubero E, García-Garzón S, Miquel J, Parra-Cid T, González-Praetorious A, Perna C, Lázaro A, Sanz-de-Villalobos E. HCV-specific CD8+ cell detection at week 12 of chronic hepatitis C treatment with PEG-interferon-α2b/ribavirin correlates with infection resolution. Cell Immunol. 2013;286:31-38. [PMID: 24287274 DOI: 10.1016/j.cellimm.2013.11.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
62 Chinnaswamy S, Chatterjee S, Boopathi R, Mukherjee S, Bhattacharjee S, Kundu TK. A single nucleotide polymorphism associated with hepatitis C virus infections located in the distal region of the IL28B promoter influences NF-κB-mediated gene transcription. PLoS One 2013;8:e75495. [PMID: 24116050 DOI: 10.1371/journal.pone.0075495] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
63 Gerold G, Pietschmann T. Opportunities and Risks of Host-targeting Antiviral Strategies for Hepatitis C. Curr Hepat Rep 2013;12:200-13. [PMID: 32214912 DOI: 10.1007/s11901-013-0187-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
64 Angulo J, Pino K, Pavez C, Biel F, Labbé P, Miquel JF, Soza A, López-Lastra M. Genetic variations in host IL28B links to the detection of peripheral blood mononuclear cells-associated hepatitis C virus RNA in chronically infected patients. J Viral Hepat. 2013;20:263-272. [PMID: 23490371 DOI: 10.1111/jvh.12076] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
65 Friborg J, Lin B, Chen C, McPhee F. Isolation and characterization of interferon lambda-resistant hepatitis C virus replicon cell lines. Virology 2013;444:384-93. [PMID: 23891156 DOI: 10.1016/j.virol.2013.07.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
66 Jiménez-Sousa MA, Berenguer J, Fernández-Rodríguez A, Micheloud D, Guzmán-Fulgencio M, Miralles P, Pineda-Tenor D, García-Álvarez M, López JC, Aldámiz-Echevarria T, Carrero A, Resino S. IL28RA polymorphism (rs10903035) is associated with insulin resistance in HIV/HCV-coinfected patients. J Viral Hepat 2014;21:189-97. [PMID: 24438680 DOI: 10.1111/jvh.12130] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
67 Han H, Noureddin M, Witthaus M, Park YJ, Hoofnagle JH, Liang TJ, Rotman Y. Temperature rise after peginterferon alfa-2a injection in patients with chronic hepatitis C is associated with virological response and is modulated by IL28B genotype. J Hepatol 2013;59:957-63. [PMID: 23850879 DOI: 10.1016/j.jhep.2013.07.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
68 Casanova JL, Abel L. The genetic theory of infectious diseases: a brief history and selected illustrations. Annu Rev Genomics Hum Genet 2013;14:215-43. [PMID: 23724903 DOI: 10.1146/annurev-genom-091212-153448] [Cited by in Crossref: 95] [Cited by in F6Publishing: 81] [Article Influence: 10.6] [Reference Citation Analysis]
69 Guzmán-Fulgencio M, Berenguer J, Rallón N, Fernández-Rodríguez A, Miralles P, Soriano V, Jiménez-Sousa MA, Cosín J, Medrano J, García-Álvarez M, López JC, Benito JM, Resino S. HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy. AIDS 2013;27:1231-8. [PMID: 23811951 DOI: 10.1097/QAD.0b013e32835f5b9c] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
70 Li ML, Xu WW, Gao YD, Guo Y, Wang WJ, Wang C, Jiang SY, Willden A, Huang JF, Zhang HT. Interferon-lambda3 (IFN-λ3) and its cognate receptor subunits in tree shrews (Tupaia belangeri): genomic sequence retrieval, molecular identification and expression analysis. PLoS One 2013;8:e60048. [PMID: 23555878 DOI: 10.1371/journal.pone.0060048] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
71 Dabbouseh NM, Jensen DM. Future therapies for chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2013;10:268-76. [PMID: 23419289 DOI: 10.1038/nrgastro.2013.17] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
72 Chayama K, Hayes CN. Interleukin-28B polymorphisms and hepatitis C virus clearance. Genome Med 2013;5:6. [PMID: 24533893 DOI: 10.1186/gm410] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
73 Nucara S, Caroleo B, Guadagnino V, Perrotti N, Trapasso F. Natural history and clinical response: "it's the virus, stupid, or is it the host?". BMC Infect Dis. 2012;12 Suppl 2:S6. [PMID: 23173731 DOI: 10.1186/1471-2334-12-S2-S6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
74 Chatel-Chaix L, Germain MA, Götte M, Lamarre D. Direct-acting and host-targeting HCV inhibitors: current and future directions. Curr Opin Virol. 2012;2:588-598. [PMID: 22959589 DOI: 10.1016/j.coviro.2012.08.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]